The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral ...
In a recent study published in the Science Bulletin, researchers comprehensively examined the composition and phenotypic features of myeloid cells in human failing hearts at a single-cell level, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results